Pathology & Molecular Medicine
"It’s a great environment to work in. I had a lot of fun and made good friends. When you’re working in a lab, it can be easy to forget that you’re working to help people. It’s easy to forget what cancer really is. I don’t have that problem.”
Doug Richardson, PhD. 2009
The Department of Pathology and Molecular Medicine is a clinical department with a major research focus in cancer, hemostasis and vascular biology. Trainees therefore have opportunities to pursue comprehensive training in basic and translational biomedical research, an example being diagnostic, predictive and prognostic biomarker research.
The graduate programs offer opportunities to pursue advanced degrees under the supervision of an exceptional group of basic, clinical and translational researchers.
With a focus on cancer – 15 of our 20 investigators are cancer biologists – our department members deliver comprehensive diagnostic laboratory and clinical services to Southeastern Ontario through the Kingston General Hospital, offering great training for the next generation of biomedical research scientists and laboratory physicians.
Queen's therefore is a great setting to learn first-hand how the fast pace of molecular genetic research is changing clinical practise, leading to exciting new diagnostic and treatment approaches for cancer and other diseases.
Trainees have many opportunities to present their work at local, national and international scientific conferences. Interactions with clinician-scientists in the context of their translational research programs or exposure to their clinical service roles provides important practical context for our trainee’s own research. The department also provides funding for travel to distant laboratories to acquire specific techniques or skills that can be established in their home labs.
Multidisciplinary exposure is a major objective of our cancer training experience. The close relationship between the department and the Cancer Research Institute and it’s three divisions (Cancer Biology and Genetics, Clinical Trials, and Cancer Care and Epidemiology) provides a unique perspective on multidisciplinary research. This is also formalized in the Collaborative Cancer Graduate Program, which is offered to all trainees engaged in cancer-focused research.
Career paths – employment opportunities
M.Sc. Graduates: are well suited to employment in Health Care (Hospital clinical labs), pharmaceutical companies, academic labs, and scientific supply companies, as well as roles in administration in academic, health care or government settings.
- Teaching positions in academic institutions or the private sector
- Technical positions in academic institutions or the private sector
- Marketing positions in private sector companies
Ph.D. Graduates: would be suited for all of these same settings, at a higher level with more leadership roles.
- Post-doctoral work
- Research and/or teaching positions at academic institutions or the private sector
- Venture capital investment advisory roles in the financial sector
M.Sc.: 2 years
Ph.D.: 4 years
Method of Completion
M.Sc. : Course work, research demonstrating experimental competence and a thesis
Ph.D.: Course work, research making novel contributions to the field of study and a thesis
CIHR Cancer Training and Collaborative Cancer Programs
These programs offer stipend support and a unique opportunity for multidisciplinary training in cancer research that includes basic molecular genetic, translational, pre-clinical drug development and clinical trials studies – as well as opportunities to work collaboratively with pharmaceutical industry partners including term placements in private sector locations.
We recommend that you contact potential supervisors in advance.
Cancer Research and Developmental Biology
- Sam Basta
- David Berman
- Susan P.C. Cole
- Scott Davey
- Bruce Elliot
- Peter Greer
- David LeBrun
- Chris Mueller
- Lois Mulligan
- Christopher J. Nicol
- Martin Petkovich
- Leda Raptis
- Michael Rauh
- Mark Ropeleski
- Waheed Sangrar
- Chandrakant Tayade
- Paul Young
- Xiaolong Yang
Human Genetics & Cytogenetics
- Harriet Feilotter
- Neil Renwick
Hemostasis & Thrombosis Research and Vascular Biology
- David.P. Lillicrap
- Donald Maurice
- Paula James
M.Sc.: $21,700 minimum
Ph.D.: $22,700 minimum
For internal, provincial and national competitive award winners, the funding package increases by 2.5%, 5% and 10% respectively.
We encourage all students to apply for additional funding through CIHR, NSERC, OGS, the Heart & Stroke Foundation, CBCF, the Department of Defence and/or the American Cancer Society.
Entering graduate students who win federal government tri-council awards are automatically provided a $5,000 (Masters) or $7,500 (PhD) top-up award by Queen’s.
Departmental Awards:The Pathology and Molecular Medicine Graduate Award is available to one outstanding entry-level graduate student in either the M.Sc. or Ph.D. program.
The Robert Kisilevsky Fund for Research Education supports a bursary program for full-time first-year Ph.D. students.
M.Sc. Program: Honours B.Sc. or equivalent in life sciences, biochemistry, biology, etc. (Students with only a general degree can be admitted for a qualifying year.). The ideal undergraduate background for the program would be one rich in molecular genetics and cell biology, in addition to foundational courses in Chemistry, Mathematics, Physiology, Biology and Biochemistry. The Queen’s Life Sciences and DBMS programs, or similar programs from other institutions provide excellent backgrounds.
Ph.D. Program: Honours B.Sc. or equivalent with first class standing or M.Sc. or equivalent with research experience
We consider all of your grades, but pay particular attention to the last two years of science-related courses.
For international students, if required, a TOEFL total score of at least 600 (paper-based) or TOEFL iBT minimum scores of: writing (24/30); speaking (22/30); reading (22/30); listening (20/30), for a total of 88/120. Applicants must have the minimum score in each test as well as the minimum overall score.
Key Dates and Deadlines
Application Deadline: February 1 to qualify for internal funding competitions, but we accept applications all year.
Notification of Acceptance: Quickly pending confirmation of a supervisor
Pathology & Molecular Medicine
Conquering Drug Resistance in Cancer Patients